Clinical Trial Update: Study of NOV-002 in Combination With Chemotherapy to Treat Lung Cancer [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating NOV-002 in combination with chemotherapy for non-small cell lung cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• NOV-002

Snippet

Sponsor: Cellectar Biosciences, Inc. | Conditions: Non Small Cell Lung Cancer | Phase 3 | Status: COMPLETED